| Blocking CGRP in migraine patients–a review of pros and cons M Deen, E Correnti, K Kamm, T Kelderman, L Papetti, E Rubio-Beltrán, ... The journal of headache and pain 18, 1-9, 2017 | 285 | 2017 |
| Gender aspects of CGRP in migraine A Labastida-Ramírez, E Rubio-Beltrán, CM Villalón, ... Cephalalgia 39 (3), 435-444, 2019 | 109 | 2019 |
| Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? E Rubio-Beltrán, A Labastida-Ramírez, CM Villalón, ... Pharmacology & therapeutics 186, 88-97, 2018 | 103 | 2018 |
| Long COVID headache C Tana, E Bentivegna, SJ Cho, AM Harriott, D García-Azorín, ... The journal of headache and pain 23 (1), 93, 2022 | 86 | 2022 |
| Characterization of binding, functional activity, and contractile responses of the selective 5‐HT1F receptor agonist lasmiditan E Rubio‐Beltrán, A Labastida‐Ramírez, KA Haanes, A van den Bogaerdt, ... British Journal of Pharmacology 176 (24), 4681-4695, 2019 | 82* | 2019 |
| PACAP38 and PAC1 receptor blockade: a new target for headache? E Rubio-Beltrán, E Correnti, M Deen, K Kamm, T Kelderman, L Papetti, ... The journal of headache and pain 19, 1-11, 2018 | 79 | 2018 |
| Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system A Labastida-Ramírez, E Rubio-Beltrán, KA Haanes, KY Chan, IM Garrelds, ... Pain 161 (5), 1092-1099, 2020 | 76 | 2020 |
| Protective effects of PACAP in ischemia D Reglodi, A Vaczy, E Rubio-Beltran, A MaassenVanDenBrink The Journal of Headache and Pain 19, 1-9, 2018 | 56 | 2018 |
| Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries E Rubio-Beltran, KY Chan, AHJ Danser, A MaassenVanDenBrink, ... Cephalalgia 40 (4), 357-366, 2020 | 54 | 2020 |
| Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine JL Bussiere, R Davies, C Dean, C Xu, KH Kim, HM Vargas, GJ Chellman, ... Regulatory Toxicology and Pharmacology 106, 224-238, 2019 | 50* | 2019 |
| Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries E Rubio-Beltrán, A Labastida-Ramírez, KA Haanes, A van den Bogaerdt, ... Cephalalgia 39 (14), 1735-1744, 2019 | 30 | 2019 |
| Exploration of purinergic receptors as potential anti-migraine targets using established pre-clinical migraine models KA Haanes, A Labastida-Ramírez, FW Blixt, E Rubio-Beltrán, CM Dirven, ... Cephalalgia 39 (11), 1421-1434, 2019 | 28 | 2019 |
| Local endothelial DNA repair deficiency causes aging-resembling endothelial-specific dysfunction PK Bautista-Niño, E Portilla-Fernandez, E Rubio-Beltrán, ... Clinical Science 134 (7), 727-746, 2020 | 27 | 2020 |
| Hypothalamic paraventricular nucleus stimulation enhances c-Fos expression in spinal and supraspinal structures related to pain modulation M Condés-Lara, G Martínez-Lorenzana, E Rubio-Beltrán, ... Neuroscience research 98, 59-63, 2015 | 26 | 2015 |
| Is CGRP Receptor Blockade Cardiovascularly Safe? Appropriate Studies Are Needed. E Rubio-Beltrán, D Duncker, CM Villalón Headache 58 (8), 1257-1258, 2018 | 22 | 2018 |
| Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman’s life: implications for the efficacy and safety of novel antimigraine medications S de Vries Lentsch, E Rubio-Beltrán, A MaassenVanDenBrink Maturitas, 2020 | 20 | 2020 |
| Understanding CGRP and cardiovascular risk E Rubio-Beltrán, AM van den Brink Calcitonin gene-related peptide (CGRP) mechanisms: focus on migraine, 131-140, 2019 | 19 | 2019 |
| Lasmiditan inhibits CGRP release in the mouse trigeminovascular system A Labastida-Ramírez, E Rubio-Beltrán, IM Garrelds, KA Haanes, KY Chan, ... Cephalalgia 37 (suppl_1), 362-363, 2017 | 16* | 2017 |
| Selective phosphodiesterase 1 inhibition ameliorates vascular function, reduces inflammatory response, and lowers blood pressure in aging animals K Golshiri, EA Ataabadi, E Rubio-Beltran, S Dutheil, W Yao, GL Snyder, ... Journal of Pharmacology and Experimental Therapeutics 378 (2), 173-183, 2021 | 10 | 2021 |
| Dietary salt modifies the blood pressure response to renin-angiotensin inhibition in experimental chronic kidney disease DM Bovée, E Uijl, D Severs, E Rubio-Beltrán, R van Veghel, ... American Journal of Physiology-Renal Physiology 320 (4), F654-F668, 2021 | 10 | 2021 |
Alejandro Labastida-RamírezKing's College London, Institute of Psychiatry, Psychology and NeurosciencesAdresse e-mail validée de kcl.ac.uk
